Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AIMMUNE THERAPEUTICS, INC.

(AIMT)
SummaryChartsNewsRatingsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société AIMMUNE THERAPEUTICS, INC.
01/22AIMMUNE THERAPEUTICS  : European Commission approves Aimmune's PALFORZIA as firs..
AQ
01/05AIMMUNE THERAPEUTICS  : European Commission approves first treatment for peanut ..
AQ
2020AIMMUNE THERAPEUTICS  : European Commission approves Aimmune's PALFORZIA as firs..
AQ
2020AIMMUNE THERAPEUTICS  : European Commission Approves Aimmune's PALFORZIA® as Fir..
BU
2020AIMMUNE THERAPEUTICS, INC.  : Termination of a Material Definitive Agreement, Co..
AQ
2020AIMMUNE THERAPEUTICS  : Receives Positive CHMP Opinion on PALFORZIA for the Trea..
AQ
2020MONTEVERDE & ASSOCIATES PC  : Files Class Action Lawsuit On Behalf Of Shareholde..
PR
2020AIMMUNE THERAPEUTICS  : Nestle Completes Acquisition of Aimmune Therapeutics
AQ
2020AIMMUNE THERAPEUTICS  : Nestle announces results of tender offer for Aimmune The..
AQ
2020Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics..
PR
2020AIMMUNE THERAPEUTICS  : Nestle commences tender offer for Aimmune Therapeutics I..
AQ
2020AIMMUNE THERAPEUTICS  : Nestlé commences tender offer for Aimmune Therapeutics, ..
PR
2020KASKELA LAW LLC  : Announces Stockholder Investigation of Aimmune Therapeutics, ..
PR
2020AIMMUNE INVESTOR ALERT BY THE FORMER : Kahn Swick & Foti, LLC Investigates Adequ..
BU
2020AIMMUNE THERAPEUTICS  : Nestle to acquire Aimmune Therapeutics
AQ
2020AIMMUNE THERAPEUTICS  : Nestlé Health Science to acquire Aimmune Therapeutics fo..
AQ
2020AIMMUNE THERAPEUTICS  : Enters Definitive Agreement with Societes des Produits N..
AQ
2020WeissLaw LLP Investigates Aimmune Therapeutics, Inc.
PR
2020Yum China, Aimmune rise; Regis, Walmart fall
AQ
2020ALERT : Rowley Law PLLC is Investigating Proposed Acquisition of Aimmune Therape..
BU
2020(AIMT) ALERT : Johnson Fistel Investigates Proposed Sale of Aimmune Therapeutics..
PR
2020AIMMUNE THERAPEUTICS, INC.  : Entry into a Material Definitive Agreement, Regula..
AQ
2020AIMMUNE THERAPEUTICS  : Enters Definitive Agreement with Sociétés des Produits N..
BU
2020AIMMUNE THERAPEUTICS  : Largest European Qualitative Study on Peanut Allergy Hig..
AQ
2020AIMMUNE THERAPEUTICS  : Largest European Qualitative Study on Peanut Allergy Hig..
BU
2020AIMMUNE THERAPEUTICS  : to Present at the 2020 Wedbush PacGrow Healthcare Virtua..
AQ
2020AIMMUNE THERAPEUTICS  : to Present at the 2020 Wedbush PacGrow Healthcare Virtua..
BU
2020AIMMUNE THERAPEUTICS  : Management's Discussion and Analysis of Financial Condit..
AQ
2020AIMMUNE THERAPEUTICS, INC.  : Results of Operations and Financial Condition, Fin..
AQ
2020AIMMUNE THERAPEUTICS : 2Q Earnings Snapshot
AQ
2020AIMMUNE THERAPEUTICS  : Announces Second Quarter 2020 Financial Results and Prov..
BU
2020AIMMUNE THERAPEUTICS  : to Host Conference Call and Webcast to Discuss Second Qu..
BU
2020AIMMUNE THERAPEUTICS  : Full Results of Aimmune's Pivotal Phase 3 European ARTEM..
AQ
2020AIMMUNE THERAPEUTICS  : Full Results of Aimmune's Pivotal Phase 3 European ARTEM..
BU
2020AIMMUNE THERAPEUTICS  : Appoints Narinder Singh as Executive Vice President of T..
BU
2020AIMMUNE THERAPEUTICS  : New Two-Year PALFORZIA Data Show On-going Safety and Eff..
AQ
2020AIMMUNE THERAPEUTICS  : New Data Show Patients Are Highly Satisfied With and Con..
AQ
2020AIMMUNE THERAPEUTICS  : New Two-Year PALFORZIA™ Data Show On-going Safety ..
BU
2020AIMMUNE THERAPEUTICS  : New Data Show Patients Are Highly Satisfied With and Con..
BU
2020AIMMUNE THERAPEUTICS  : to Present at the Goldman Sachs 41st Annual Global Healt..
BU
2020AIMMUNE THERAPEUTICS  : New PALFORZIA Data on Long-Term Safety, Efficacy and Imm..
AQ
2020AIMMUNE THERAPEUTICS  : New PALFORZIA™ Data on Long-Term Safety, Efficacy ..
BU
2020AIMMUNE THERAPEUTICS  : Largest European Quantitative Study on Peanut Allergy Co..
AQ
2020AIMMUNE THERAPEUTICS, INC.  : Submission of Matters to a Vote of Security Holder..
AQ
2020AIMMUNE THERAPEUTICS  : Largest European Quantitative Study on Peanut Allergy Co..
BU
2020AIMMUNE THERAPEUTICS  : to Present at the RBC Capital Markets 2020 Global Health..
BU
2020AIMMUNE THERAPEUTICS : 1Q Earnings Snapshot
AQ
2020AIMMUNE THERAPEUTICS  : Management's Discussion and Analysis of Financial Condit..
AQ
2020AIMMUNE THERAPEUTICS, INC.  : Results of Operations and Financial Condition, Fin..
AQ
2020AIMMUNE THERAPEUTICS  : Announces First Quarter 2020 Financial Results and Provi..
BU
2020AIMMUNE THERAPEUTICS  : to Host Conference Call and Webcast to Discuss First Qua..
BU
2020AIMMUNE THERAPEUTICS  : to Present at the 19th Annual Needham Virtual Healthcare..
BU
2020AIMMUNE THERAPEUTICS  : Announces First U.S. Patients Are Being Treated with New..
AQ
2020AIMMUNE THERAPEUTICS  : Announces New PALFORZIA Data Suggesting Increased Desens..
AQ
2020AIMMUNE THERAPEUTICS  : Announces First U.S. Patients Are Being Treated with New..
BU
2020AIMMUNE THERAPEUTICS  : Announces New PALFORZIA™ Data Suggesting Increased..
BU
2020AIMMUNE THERAPEUTICS : 4Q Earnings Snapshot
AQ
2020AIMMUNE THERAPEUTICS  : Management's Discussion and Analysis of Financial Condit..
AQ
2020AIMMUNE THERAPEUTICS, INC.  : Results of Operations and Financial Condition, Fin..
AQ
2020AIMMUNE THERAPEUTICS  : Announces Fourth Quarter and Full Year 2019 Financial Re..
BU
2020AIMMUNE THERAPEUTICS  : to Present at Upcoming Investor Conferences
BU
2020AIMMUNE THERAPEUTICS  : to Present New Clinical Data at AAAAI Annual Meeting
BU
2020AIMMUNE THERAPEUTICS  : to Host Conference Call and Webcast to Discuss Fourth Qu..
BU
2020AIMMUNE THERAPEUTICS  : Nestle Health Science further invests in Aimmune Therape..
AQ
2020AIMMUNE THERAPEUTICS  : Announces Additional $200 Million Equity Investment by N..
AQ
2020AIMMUNE THERAPEUTICS  : Licenses Exclusive Worldwide Rights to Xencor's XmAb7195..
AQ
2020AIMMUNE THERAPEUTICS, INC.  : Entry into a Material Definitive Agreement, Creati..
AQ
2020AIMMUNE THERAPEUTICS  : Announces Additional $200 Million Equity Investment by N..
BU
2020AIMMUNE THERAPEUTICS  : FDA Approves Aimmune's PALFORZIA as First Treatment for ..
AQ
2020AIMMUNE THERAPEUTICS, INC.  : Other Events, Financial Statements and Exhibits (f..
AQ
2020AIMMUNE THERAPEUTICS  : FDA Approves Aimmune's PALFORZIA™ as First Treatme..
BU
2020AIMMUNE THERAPEUTICS  : to Present at the 38th Annual J.P. Morgan Healthcare Con..
BU
2019AIMMUNE THERAPEUTICS, INC.  : Change in Directors or Principal Officers, Financi..
AQ
2019AIMMUNE THERAPEUTICS  : to Participate in Three Upcoming Investor Conferences
AQ
2019AIMMUNE THERAPEUTICS  : to Participate in Three Upcoming Investor Conferences
BU
1  2  3Next